• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aptinyx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    7/3/23 1:31:15 PM ET
    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APTX alert in real time by email
    0001674365 false 0001674365 2023-06-30 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 30, 2023

     

     

     

    APTINYX INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38535   47-4626057

    (State or other jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification Number)

     

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Suite 101

    Foxborough, MA

      02035
    (Address of registrant’s principal executive office)   (Zip code)

     

    (508) 543-1720

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.01 per share   APTX   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

    Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Director Resignation

     

    On June 30, 2023, Robert Hombach notified Aptinyx, Inc. (the “Company”) of his resignation as a member of the Company’s board of directors (the “Board”), effective immediately. Mr. Hombach’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

     

    Officer Departure

     

    On June 30, 2023, Andrew Kidd, stepped down from his position as interim chief executive officer and principal executive officer, principal financial officer and principal accounting officer of the Company.

     

    Officer Appointment

     

    On June 30, 2023, following Mr. Kidd’s resignation, Craig Jalbert was appointed principal executive officer, principal financial officer and principal accounting officer of the Company. As previously disclosed in the Company’s Form 8-K filed with the Securities and Exchange Commission on May 5, 2023, Mr. Jalbert will be compensated in the amount of $10,000 per month. Mr. Jalbert will be compensated in the amount of $50,000 per year for a period of three years following the filing of the certificate of dissolution with the Secretary of State of the State of Delaware. There is no arrangement or understanding pursuant to which Mr. Jalbert was appointed to be an officer of the Company. There are no family relationships between Mr. Jalbert and any director or executive officer of the Company, and Mr. Jalbert has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.    

     

    Item 5.07 - Submission of Matters to a Vote of Security Holders.

     

    On June 30, 2023, at a special meeting of stockholders (the “Special Meeting”) of Aptinyx Inc. (the “Company”), the Company’s stockholders approved the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the “Plan of Dissolution”), which authorizes the board of directors of the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution. The proposal is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 2, 2023.

     

    The number of shares of common stock entitled to vote at the Special Meeting was 67,715,718. The number of shares of common stock present or represented by proxy at the Special Meeting was 35,078,510.

     

    Stockholders approved the proposal, with 33,956,016 votes cast for, 1,061,642 votes cast against and 60,852 votes abstained. There were no broker non-votes regarding the proposal.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: July 3, 2023 APTINYX INC.
         
      By: /s/ Craig Jalbert
        Craig Jalbert
        President

     

     

     

     

     

    Get the next $APTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APTX

    DatePrice TargetRatingAnalyst
    4/7/2022Outperform → Mkt Perform
    William Blair
    12/20/2021$12.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $APTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

      Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

      4/23/24 8:00:00 AM ET
      $APTX
      $BAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

      Aptinyx Inc. (NASDAQ:APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). The study was halted in February prior to its completion in support of the company's preservation of capital. In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support continued advancement of the development program by Aptinyx. In March, Aptinyx engaged Ladenburg Thalmann as its exclusive fi

      3/30/23 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

      NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will terminate its ongoing study of NYX-783 in PTSD and analyze the data available to date Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Across the overall study population, NYX-

      2/27/23 4:03:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    SEC Filings

    See more
    • Aptinyx Inc. filed SEC Form 8-K: Other Events

      8-K - Aptinyx Inc. (0001674365) (Filer)

      12/21/23 10:52:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Inc. filed SEC Form 8-K: Other Events

      8-K - Aptinyx Inc. (0001674365) (Filer)

      12/18/23 5:00:17 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Aptinyx Inc.

      25-NSE - Aptinyx Inc. (0001674365) (Subject)

      7/10/23 6:04:47 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Financials

    Live finance-specific insights

    See more
    • Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

      Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor

      11/8/22 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'

      10/18/22 7:45:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights

       Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the

      8/4/22 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

      Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

      4/23/24 8:00:00 AM ET
      $APTX
      $BAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. "Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors," said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. "His expertise in research and clinical development is amplified by the successful development programs he has overseen across a rang

      10/20/21 7:57:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women's Hospital. "We are delighted to welcome Joan to the Aptinyx Board of Directors," said Norbert Riedel, Ph.D., chief executive offic

      5/10/21 7:57:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Khanna Ashish

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:17:54 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Riedel Norbert G

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:17:01 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kidd Andrew

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:16:09 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aptinyx downgraded by William Blair

      William Blair downgraded Aptinyx from Outperform to Mkt Perform

      4/7/22 1:13:54 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Aptinyx with a new price target

      SVB Leerink reiterated coverage of Aptinyx with a rating of Outperform and set a new price target of $10.00 from $12.00 previously

      12/20/21 4:47:19 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx downgraded by JP Morgan

      JP Morgan downgraded Aptinyx from Neutral to Underweight

      1/29/21 8:18:50 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aptinyx Inc. (Amendment)

      SC 13G/A - Aptinyx Inc. (0001674365) (Subject)

      2/9/24 5:16:02 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)

      SC 13D/A - Aptinyx Inc. (0001674365) (Subject)

      6/27/23 2:13:31 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)

      SC 13D/A - Aptinyx Inc. (0001674365) (Subject)

      3/16/23 4:19:28 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care